Welcome to


Initially targeting Refractory or Unexplained Chronic Cough, a common, long-lasting and debilitating condition, experienced by millions of people worldwide, for which there is no approved treatment.

A unique approach

NeRRe Therapeutics is a UK based clinical stage company progressing a unique portfolio of three neurokinin-1 antagonists (NK-1RAs) for the treatment of common, chronic and debilitating conditions, caused by neural hypersensitivity related to Substance P/ NK-1 receptor system dysfunction. The lead NK-1RA compound orvepitant has just completed a multinational Phase 2b dose range finding study “VOLCANO-2”, in patients suffering from Refractory or Unexplained Chronic Cough with positive results.

Latest News

Contact Us

For general, media or partnership enquiries, get in touch with us:

Contact Us
Contact Us

Please fill out the form to get in touch with us.

Not readable? Change text. captcha txt